Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007299', 'term': 'Insect Bites and Stings'}], 'ancestors': [{'id': 'D001733', 'term': 'Bites and Stings'}, {'id': 'D011041', 'term': 'Poisoning'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C018904', 'term': 'dexchlorpheniramine'}, {'id': 'D005782', 'term': 'Gels'}], 'ancestors': [{'id': 'D003102', 'term': 'Colloids'}, {'id': 'D045424', 'term': 'Complex Mixtures'}, {'id': 'D004304', 'term': 'Dosage Forms'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 90}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2011-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-11', 'completionDateStruct': {'date': '2011-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-11-02', 'studyFirstSubmitDate': '2010-11-02', 'studyFirstSubmitQcDate': '2010-11-02', 'lastUpdatePostDateStruct': {'date': '2010-11-03', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-11-03', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pruritus Intensity at Insect Bite Site, Evaluated With a 10 Point Visual Analogic Scale (VAS)', 'timeFrame': '7 days'}], 'secondaryOutcomes': [{'measure': 'Composite Clinical Evaluation of Erythema, Pruritus and Papule Formation, Performed by the Investigator Using a 4-point Scale for Each One of the Parameters (Absent, Mild, Moderate, Intense). This Evaluation Constitutes the Insect Bite Score.', 'timeFrame': '7 days'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Insect bites', 'Dexchlorpheniramine', 'Gel', 'Cream'], 'conditions': ['Insect Bites']}, 'descriptionModule': {'briefSummary': 'Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms. Dexchlorpheniramine maleate 1% cream is a topical anti-histaminic formulation approved by ANVISA in Brazil for the relief of skin irritation and allergies, including the ones caused by insect bites. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% gel) with the standard preparation (1% cream) for the relief of insect bite related symptoms and to demonstrate the safety of both preparations.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '60 Years', 'minimumAge': '2 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Presence of papules resulting from insect bites within the last 72 hours;\n* Presence of symmetric lesions to compare one side to the other;\n* Compliance of the subject to the treatment protocol;\n* Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old.\n\nExclusion Criteria:\n\n* Pregnancy or risk of pregnancy;\n* Lactation;\n* Use of topical or systemic anti-inflammatory, anti-histaminics or immunosuppressive drugs within the last 48 hours prior to the study;\n* History of atopy or allergic diseases;\n* History of allergy of any component of the formulations;\n* Other conditions considered by the investigator as reasonable for non-eligibility.'}, 'identificationModule': {'nctId': 'NCT01233934', 'briefTitle': 'Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites', 'organization': {'class': 'INDUSTRY', 'fullName': 'Mantecorp Industria Quimica e Farmaceutica Ltd.'}, 'orgStudyIdInfo': {'id': 'ERP 185v3-10'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Dexchlorpheniramine 1% Cream', 'interventionNames': ['Drug: Dexchlorpheniramine 1% Cream']}, {'type': 'EXPERIMENTAL', 'label': 'Dexchlorpheniramine 1% Gel', 'interventionNames': ['Drug: Dexchlorpheniramine 1% Gel']}], 'interventions': [{'name': 'Dexchlorpheniramine 1% Gel', 'type': 'DRUG', 'description': 'Small amount applied over the lesion twice a day for 7 days.', 'armGroupLabels': ['Dexchlorpheniramine 1% Gel']}, {'name': 'Dexchlorpheniramine 1% Cream', 'type': 'DRUG', 'description': 'Small amount applied over the lesion twice a day for 7 days.', 'armGroupLabels': ['Dexchlorpheniramine 1% Cream']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06023000', 'city': 'Osasco', 'state': 'São Paulo', 'country': 'Brazil', 'contacts': [{'name': 'Sergio Schalka, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medcin Instituto da Pele Ltda.', 'geoPoint': {'lat': -23.5325, 'lon': -46.79167}}], 'centralContacts': [{'name': 'Sergio Schalka, MD', 'role': 'CONTACT', 'email': 'medci004@terra.com.br', 'phone': '551136811334'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mantecorp Industria Quimica e Farmaceutica Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Celso Sustovich', 'oldOrganization': 'Medical Director'}}}}